EDX Medical Group Plc Placing to raise £1,725,000
26 Abril 2023 - 10:15AM
UK Regulatory
TIDMEDX
This announcement contains inside information as stipulated under
the UK version of the Market Abuse Regulation No 596/2014 which is part of
English law by virtue of the European (Withdrawal) Act 2018, as amended. On
publication of this announcement via a regulatory information service, this
information is considered to be in the public domain and such persons shall
therefore cease to be in possession of inside information.
LONDON: April 26, 2023
EDX Medical Group Plc
Placing to raise £1,725,000
EDX Medical Group plc ("EDX Medical" or the "Company"), which develops
innovative digital diagnostic products and services supporting personalised
treatment solutions for cancer, heart disease, neurology and infectious
diseases, is pleased to announce that the Company has raised a total of £
1,725,000 via the issue of 28,750,000 new ordinary shares in the Company, at 6
pence per share ("Placing").
Bridgemere Securities Ltd ("Bridgemere") has invested £1,500,000 in the
Placing. Further, Bridgemere has also bought a further 7,720,000 ordinary
shares in the market between 20 and 21 April 2023. Bridgemere is now the second
largest shareholder in EDX Medical following its investment.
Paul Thandi, CBE, DL, has invested £200,000 in the Placing.
Robert Marshall, founder and executive chairman of Martlet Capital, also
increased his shareholding in the Company investing a further £25,000 in the
Placing.
Professor Sir Christopher Evans, founder of EDX Medical, said: "We are
delighted that experienced investors such as Bridgemere - led by the renowned
Steve Morgan - as well as Paul Thandi and Robert Marshall share our vision for
the company and are investing in the innovations we are delivering in digital
diagnostics, which we believe will make a significant contribution to the
development of advanced digital diagnostic solutions to accelerate the
availability of cost-effective personalised treatments for patients with a
range of major diseases."
Paul Thandi has been CEO of the NEC Group for 16 years, spearheading its
acquisition by Blackstone in 2021 for £800m. He is an experienced board
director, investor and philanthropist who supports a number of charitable
causes including cancer charities.
Application has been made for the 28,750,000 Placing shares to be admitted to
trading on or about 3 May 2023.
Total Voting Rights
In accordance with the Financial Conduct Authority's Disclosure and
Transparency Rules, the Company hereby announces that following the placing, it
has 281,250,000 ordinary shares of 1 pence each ("Ordinary Shares") in issue,
each share carrying the right to one vote.
The above figure of 281,250,000 Ordinary Shares may be used by shareholders in
the Company as the denominator for the calculations by which they will
determine if they are required to notify their interest in, or a change to
their interest in, the share capital of the Company under the Financial Conduct
Authority's Disclosure and Transparency Rules.
The directors of the EDX Medical accept responsibility for the contents of this
announcement.
For more information, please contact:
EDX Medical PLC
Dr Mike Hudson
Tel: 07812345301
Peterhouse:
Guy Miller
Tel: 020 7220 9795
Media House International,
Ramsay Smith
Tel: +44 (0) 7788 414856:
email: ramsay@mediahouse.co.uk
Notes for Editors:
About EDX Medical Group
EDX Medical develops and delivers innovative digital diagnostic products and
services for cancer, heart disease, neurology and infectious disease testing,
helping to predict disease risk, inform clinical decision-making and accelerate
the development of new medicines. The company is listed on the Access Segment
of the AQSE Growth Market (TIDM: EDX).
EDX Medical was founded by Professor Sir Christopher Evans, OBE, a medical and
life sciences entrepreneur with more than 30 years of experience in the sector,
together with CEO, Dr Mike Hudson.
By translating clinical insights into pragmatic solutions combining advanced
biological and digital technologies, EDX Medical seeks to cost-effectively
improve the detection of disease risk and personalise disease management in a
timely fashion. Early disease detection and risk prediction is the most
impactful way of reducing deaths and lowering the future costs of healthcare
provision globally.
EDX Medical operates a molecular biology and diagnostics laboratory
in Cambridge, UK, and the 100%-owned subsidiary "Torax Biosciences Ltd" with a
satellite laboratory in Ireland. EDX Medical provides testing and genomic
sequencing services, undertakes quality assurance and has established expertise
in the design, development, validation and sourcing of diagnostic testing
solutions to ISO 13485. Key laboratory tests performed by the Company have been
accredited to ISO 15189 by the United Kingdom Accreditation Service (UKAS)..
www.edxmedical.co.uk
https://www.toraxbiosciences.co.uk/
END
(END) Dow Jones Newswires
April 26, 2023 09:15 ET (13:15 GMT)
EDX Medical (AQSE:EDX)
Gráfico Histórico do Ativo
De Ago 2024 até Set 2024
EDX Medical (AQSE:EDX)
Gráfico Histórico do Ativo
De Set 2023 até Set 2024